According to GlobalData, there will be 1,463,151 diagnosed incident cases of NSCLC in 2032 in the eight major markets. Credit: males_design via Shutterstock.

MAIA Biotechnology has reported new positive efficacy data from its Phase II THIO-101 clinical trial of THIO (6-thio-2′-deoxyguanosine) sequenced with checkpoint inhibitor cemiplimab (Libtayo) to treat advanced non-small cell lung cancer (NSCLC).

The results were presented during the ongoing American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago until 4 June.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Updated data from the THIO-101 study (NCT05208944) show a disease control rate (DCR) of 85% from THIO and Libtayo in NSCLC patients who failed two or more standard-of-care therapy regimens. The primary objectives of the trial are to examine the safety and tolerability of THIO as an anticancer drug and as an immune system primer, as well as the clinical efficacy of THIO in the form of overall response rate (ORR).

The company previously announced results in March 2024, demonstrating that the overall response rate (ORR) was 38% for the combination of THIO 180mg plus Libtayo in third-line NSCLC patients who did not respond to immune checkpoint inhibitors in previous lines of therapy, irrespective of chemotherapy status.

The trial is designed to analyse if low doses of THIO administered before Libtayo can boost and prolong the immune response in advanced NSCLC patients who have not responded or have developed resistance to first-line treatments containing another checkpoint inhibitor.

See Also:

THIO is a first-in-class small molecule cancer telomere-targeting agent. The candidate has received three orphan drug designations, including one each for glioblastoma multiforme (GBM) in 2023, hepatocellular carcinoma (HCC), and small cell lung cancer (SCLC) in 2022.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the announcement accompanying the data, MAIA CEO Vlad Vitoc said: “The data presented at ASCO advances THIO’s excellent clinical profile as a strong, safe, and highly effective alternative for patients who progressed following chemotherapy and other available treatments. We eagerly anticipate full efficacy data from THIO-101 in the second half of this year.”

According to a report on GlobalData’s Pharma Intelligence Center, the diagnosed incident cases of NSCLC are expected to increase from 1,097,467 cases in 2022 to 1,463,151 cases in 2032 in the eight major markets (UK, US, France, Spain, Italy, Germany, Japan, and urban China).

MAIA is also researching other drug treatments, using telomere-targeting agents as a foundation. The company’s programme aims to discover new compounds with potentially improved specificity toward cancer cells relative to normal cells and increased anticancer activity.